146 related articles for article (PubMed ID: 15350030)
1. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases.
Alcedo JC; Fábrega JM; Arosemena JR; Urrutia A
Head Neck; 2004 Sep; 26(9):829-31. PubMed ID: 15350030
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands.
Pfeffer MR; Talmi Y; Catane R; Symon Z; Yosepovitch A; Levitt M
Oral Oncol; 2007 Jan; 43(1):33-6. PubMed ID: 16757202
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands.
Faivre S; Raymond E; Casiraghi O; Temam S; Berthaud P
J Clin Oncol; 2005 Sep; 23(25):6271-3; author reply 6273-4. PubMed ID: 16135502
[No Abstract] [Full Text] [Related]
5. Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma.
Ghosal N; Mais K; Shenjere P; Julyan P; Hastings D; Ward T; Ryder WD; Bruce I; Homer J; Slevin NJ
Br J Oral Maxillofac Surg; 2011 Oct; 49(7):510-5. PubMed ID: 21071117
[TBL] [Abstract][Full Text] [Related]
6. Effects of imatinib mesylate on adenoid cystic carcinomas.
Ochel HJ; Gademann G; Röcken C; Wördehoff H
Anticancer Res; 2005; 25(5):3659-64. PubMed ID: 16101197
[TBL] [Abstract][Full Text] [Related]
7. Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate.
Lin CH; Yen RF; Jeng YM; Tzen CY; Hsu C; Hong RL
Head Neck; 2005 Dec; 27(12):1022-7. PubMed ID: 16265655
[TBL] [Abstract][Full Text] [Related]
8. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract][Full Text] [Related]
9. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of imatinib in unresectable hepatocellular carcinoma.
Lin AY; Fisher GA; So S; Tang C; Levitt L
Am J Clin Oncol; 2008 Feb; 31(1):84-8. PubMed ID: 18376233
[TBL] [Abstract][Full Text] [Related]
13. Management of adenoid cystic carcinoma of minor salivary glands.
Triantafillidou K; Dimitrakopoulos J; Iordanidis F; Koufogiannis D
J Oral Maxillofac Surg; 2006 Jul; 64(7):1114-20. PubMed ID: 16781345
[TBL] [Abstract][Full Text] [Related]
14. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
15. [Imatinib in gastrointestinal stromal tumor treatment--results from University Hospital Centre Zagreb].
Vrbanec D; Petricević B; Majerović M; Stern-Padovan R; Belev B; Skegro M; Herceg D; Plestina S; Dedić-Plavetić N; Jakić-Razumović J
Lijec Vjesn; 2006; 128(5-6):161-6. PubMed ID: 16910417
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome.
Payne SM; Kovacs MJ
Ann Pharmacother; 2004; 38(7-8):1215-8. PubMed ID: 15187212
[TBL] [Abstract][Full Text] [Related]
17. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
Anticancer Drugs; 2006 Jul; 17(6):649-55. PubMed ID: 16917210
[TBL] [Abstract][Full Text] [Related]
18. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies.
Dodd RL; Slevin NJ
Oral Oncol; 2006 Sep; 42(8):759-69. PubMed ID: 16757203
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate].
Haugland HK; Jebsen NL; Mannelqvist M; Skar R; Eide J; Øvrebø K; Horn A; Jensen DK; Monge OR; Lilleng PK
Tidsskr Nor Laegeforen; 2005 Apr; 125(7):868-72. PubMed ID: 15815732
[TBL] [Abstract][Full Text] [Related]
20. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.
Bonvalot S; Eldweny H; Péchoux CL; Vanel D; Terrier P; Cavalcanti A; Robert C; Lassau N; Cesne AL
Ann Surg Oncol; 2006 Dec; 13(12):1596-603. PubMed ID: 16957966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]